Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Balance Sheet

v3.20.4
Condensed Consolidated Interim Balance Sheet - USD ($)
Dec. 31, 2020
Jun. 30, 2020
Current assets    
Cash and cash equivalents $ 17,158,000 $ 2,392,000
Prepaid expenses and deposits 551,000 356,000
Interest, taxes and other receivables 8,000 9,000
Deferred loan costs   94,000
Current assets 17,717,000 2,851,000
Clinical trial deposit 2,600,000  
Intangible assets - net   2,000
Property and equipment 172,000  
Deferred financing costs   85,000
Total assets 20,489,000 2,938,000
Current liabilities    
Accounts payable and accrued liabilities 1,965,000 2,011,000
Loan payable, net of deferred loan costs 473,000  
Related party payables 289,397 663,865
Current liabilities 2,727,000 2,675,000
Milestone payment liability 177,000  
Total liabilities 2,904,000 2,675,000
Stockholders’ equity    
Common stock Authorized 95,000 shares at September 30, 2020 and June 30, 2020, $0.001 par value 24,466 issued at September 30, 2020 (June 30, 2020 - 11,458) 25,000 11,000
Additional paid-in capital 93,551,000 65,148,000
Accumulated deficit (97,846,000) (69,721,000)
Accumulated other comprehensive income 21,000 21,000
Total stockholders’ equity 17,585,000 263,000
Total liabilities and stockholders’ equity 20,489,000 2,938,000
Preferred Stock Series A    
Stockholders’ equity    
Preferred stock 279,000 279,000
Preferred Stock Series B    
Stockholders’ equity    
Preferred stock 4,257,000 4,525,000
Total stockholders’ equity 4,257,000 $ 4,525,000
Preferred Stock Series C    
Stockholders’ equity    
Preferred stock $ 17,298,000